Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMONCUL)

Drug Name
9-BENZYL-9H-ADENINE Drug Info
Synonyms
9-Benzyladenine; 4261-14-7; 9-benzyl-9H-purin-6-amine; N9-Benzyladenine; 9-Benzylaminopurine; ADENINE, 9-BENZYL-; 9-Bap; 9-Benzyl-6-aminopurine; N(sup 9)-Benzyladenine; 9-BENZYL-9H-ADENINE; 9-Benzyl-9H-purin-6-ylamine; 9H-Purin-6-amine, 9-(phenylmethyl)-; CCRIS 6908; SQ 21611; 9-benzylpurin-6-amine; NSC 35649; 9-(Phenylmethyl)-9H-purin-6-amine; CHEMBL266094; 9H-Purin-6-amine,9-(phenylmethyl)-; AC1L2FWA; MLS000660735; SCHEMBL104932; 9-Benzyl-9H-purine-6-amine; CTK4I6467; DTXSID70195371; MRHCSNNEUHXNIC-UHFFFAOYSA-N; HMS2676M21
Indication
Disease Entry ICD 11 Status REF
Discovery agent N.A. Investigative [1]
Cross-matching ID
PubChem CID
20262
CAS Number
CAS 4261-14-7
TTD Drug ID
DMONCUL

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Approved Drug(s)
Clinical Trial Drug(s)
Download the Complete Related Drug List
Drug(s) Targeting Adenosine A2a receptor (ADORA2A)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Caffeine DMKBJWP Allergic rhinitis CA08.0 Approved [2]
Istradefylline DM20VSK Parkinson disease 8A00.0 Approved [3]
Regadenoson DM76VHG Radionuclide imaging N.A. Approved [4]
Tozadenant DMATC14 Parkinson disease 8A00.0 Phase 3 [5]
Binodenoson DMVHF8G Hypertension BA00-BA04 Phase 3 [6]
Apadenoson DMD8QTC Coronary artery disease BA80 Phase 3 [7]
Tonapofylline DMBH316 Acute and chronic heart failure BD1Z Phase 2 [8]
Dexefaroxan DMTY4KN Parkinson disease 8A00.0 Phase 2 [9]
AMP-579 DMJ4GPR Hyperlipidaemia 5C80 Phase 2 [10]
BIIB014 DMH7RJ1 Parkinson disease 8A00.0 Phase 2 [11]
⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas
Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Adenosine A2a receptor (ADORA2A) TTM2AOE AA2AR_HUMAN Inhibitor [1]

References

1 8-Bromo-9-alkyl adenine derivatives as tools for developing new adenosine A2A and A2B receptors ligands. Bioorg Med Chem. 2009 Apr 1;17(7):2812-22.
2 Caffeine as a psychomotor stimulant: mechanism of action. Cell Mol Life Sci. 2004 Apr;61(7-8):857-72.
3 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2019
4 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
5 Tozadenant (SYN115) in patients with Parkinson's disease who have motor fluctuations on levodopa: a phase 2b, double-blind, randomised trial. Lancet Neurol. 2014 Aug;13(8):767-76.
6 Coronary circulation responses to binodenoson, a selective adenosine A2A receptor agonist. Am J Cardiol. 2007 Jun 1;99(11):1507-12.
7 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 3290).
8 2-Amino-5-benzoyl-4-phenylthiazoles: Development of potent and selective adenosine A1 receptor antagonists. Bioorg Med Chem. 2010 Mar 15;18(6):2195-2203.
9 The pipeline and future of drug development in schizophrenia. Mol Psychiatry. 2007 Oct;12(10):904-22.
10 Adenosine A1/A2a receptor agonist AMP-579 induces acute and delayed preconditioning against in vivo myocardial stunning. Am J Physiol Heart Circ Physiol. 2004 Dec;287(6):H2746-53.
11 Novel pharmacological targets for the treatment of Parkinson's disease. Nat Rev Drug Discov. 2006 Oct;5(10):845-54.